Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Breast Cancer Monthly Minutes

CDK4/6 inhibitors combined with anti-HER2 agents in HER2-low expressing MBC cases warrant prospective evaluations.
Evidence from studies indicates that common genetic and epigenetic features of male and female breast cancer are not shared, but further studies are warranted.
Breast cancer survivors should be closely monitored and offered appropriate evidence-based treatment for fatigue, cognitive dysfunction, and sexual problems.
An analysis of racial minority groups treated for breast cancer demonstrates worse survival outcomes.
Breast cancer’s initiation, progression, and behavior may be affected by chronic inflammation.
Practice-directed and targeted interventions enhance detection of risk through genetic counseling and testing.
Differences in patient characteristics, CDK4/6 inhibitor schedule, treatment duration, and discontinuation rates may contribute to differences in outcomes.
Quality of social support may impact patients’ disease understanding and should be considered when creating clinical interventions.
To reduce cancer-related cognitive impairment, there may be a benefit to targeting specific inflammatory processes.
A significant increase in clinical trial accruals resulted from dedicating a single employee to screening patients, suggesting a potential paradigm for limited resource settings.
Page 1 of 4
Results 1 - 10 of 35